During a London R&D meeting in November of 2018, Swiss giant Novartis AG announced it was paring back its pipeline from 430 products to 340.
Find out which areas are being phased out, and which are planned to become the company’s main focus, including treatments for asthma and multiple sclerosis, and an immuno-oncology offering, as Scrip examines the short- and long-term pipeline for Novartis, under the direction of CEO Vas Narasimhan.
Find out which areas are being phased out, and which are planned to become the company’s main focus, including treatments for asthma and multiple sclerosis, and an immuno-oncology offering, as Scrip examines the short- and long-term pipeline for Novartis, under the direction of CEO Vas Narasimhan.
